Paolo Tarantino, Research Fellow Dana-Farber Cancer Institute and Harvard Medical Schoolpost, shared on X:
“Camizestrant now approved in Europe.
New treatments are always welcome. Though implementation of cami will require sequential ctDNA testing without PD, which may not be immediately available across .
Hoping to have the drug also available in the soon.”
You can also read:
